Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE

NCT01539018 is registered in ClinicalTrials.gov with Egyptian Society of Liver Cancer as lead sponsor.

NCT NCT01539018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01539018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE
Lead sponsor
Egyptian Society of Liver Cancer
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2012
Completion date
January 31, 2015
Enrollment
77 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma